PhenoSense Entry™ is the only commercially available assay for testing resistance to entry inhibitors. The assay assesses resistance to Fuzeon® (enfuvirtide), which interacts with glycoprotein gp41 of the HIV envelope.
Genotyping may be insufficient because recent data have shown that areas outside of the envelope impact Fuzeon® susceptibility. This may explain why a wide range of fold changes have been observed with similar mutational patterns.
PhenoSense Entry™ also assesses resistance to entry inhibitors that interact with gp120 (eg, chemokine receptor antagonists, attachment inhibitors), and is used in their clinical development. It is the standard for assessing resistance to current and future entry inhibitors.
Click here to learn more about PhenoSense GT™ technology Click here to learn more about PhenoSense™ HIV technology Click here to learn more about GeneSeq™ HIV technology
Get the latest information on
individualized medicine
